These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26715378)

  • 21. Ethical preparedness of data monitoring committees (DMCs) to oversee international clinical trials: a qualitative descriptive study.
    Hinga A; Ibrahim A; Vintimilla D; Jones M; Eckstein L; Rid A; Shah SK; Kamuya D
    BMJ Glob Health; 2024 Aug; 9(8):. PubMed ID: 39182924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases.
    Filippatos GS; de Graeff P; Bax JJ; Borg JJ; Cleland JG; Dargie HJ; Flather M; Ford I; Friede T; Greenberg B; Henon-Goburdhun C; Holcomb R; Horst B; Lekakis J; Mueller-Velten G; Papavassiliou AG; Prasad K; Rosano GM; Severin T; Sherman W; Stough WG; Swedberg K; Tavazzi L; Tousoulis D; Vardas P; Ruschitzka F; Anker SD
    Eur J Heart Fail; 2017 Apr; 19(4):449-456. PubMed ID: 28271595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ensuring trial conduct is consistent with trial design: assumption is the enemy of quality.
    Kelly J; Hounsome B; Lambert G; Murphy C
    Trials; 2019 Jul; 20(1):416. PubMed ID: 31291974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Data monitoring committees: Promoting best practices to address emerging challenges.
    Fleming TR; DeMets DL; Roe MT; Wittes J; Calis KA; Vora AN; Meisel A; Bain RP; Konstam MA; Pencina MJ; Gordon DJ; Mahaffey KW; Hennekens CH; Neaton JD; Pearson GD; Andersson TL; Pfeffer MA; Ellenberg SS
    Clin Trials; 2017 Apr; 14(2):115-123. PubMed ID: 28359194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsors.
    Bhattacharyya A; Gallo P; Crisp A; LaVange L; Molenberghs G; Pétavy F; Seltzer J
    Biom J; 2019 Sep; 61(5):1232-1241. PubMed ID: 30589102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stopping guidelines for an effectiveness trial: what should the protocol specify?
    Tyson JE; Pedroza C; Wallace D; D'Angio C; Bell EF; Das A
    Trials; 2016 May; 17(1):240. PubMed ID: 27165260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Data monitoring in randomized controlled trials: surveys of recent practice and policies.
    Clemens F; Elbourne D; Darbyshire J; Pocock S;
    Clin Trials; 2005; 2(1):22-33. PubMed ID: 16279576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Playing safe and preserving integrity: making the FDA model work.
    Wittes J
    Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ethical issues during the conduct of clinical trials.
    Silverman H
    Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
    McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
    [No Abstract]   [Full Text] [Related]  

  • 35. Guidelines for clinical investigator involvement in industry-sponsored clinical trials. SAEM Research Committee.
    Panacek EA; Lewis RJ
    Acad Emerg Med; 1995 Jan; 2(1):43-5. PubMed ID: 7606612
    [No Abstract]   [Full Text] [Related]  

  • 36. A note on the draft International Council for Harmonisation guidance on estimands and sensitivity analysis.
    Mehrotra DV
    Clin Trials; 2019 Aug; 16(4):339-344. PubMed ID: 30977390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A joint industry-sponsored data monitoring committee model for observational, retrospective drug safety studies in the real-world setting.
    Major-Pedersen A; McCullen MK; Sabol ME; Adetunji O; Massaro J; Neugut AI; Sosa JA; Hollenberg AN
    Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):9-16. PubMed ID: 33179845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials.
    Sydes MR; Spiegelhalter DJ; Altman DG; Babiker AB; Parmar MK;
    Clin Trials; 2004 Feb; 1(1):60-79. PubMed ID: 16281463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Responsibilities of Data Monitoring Committees: Consensus Recommendations.
    Bierer BE; Li R; Seltzer J; Sleeper LA; Frank E; Knirsch C; Aldinger CE; Levine RJ; Massaro J; Shah A; Barnes M; Snapinn S; Wittes J
    Ther Innov Regul Sci; 2016 Sep; 50(5):648-659. PubMed ID: 30231760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.